
HDAX Therapeutics - Histone Deacetylase Targeting Drug Discovery






Stage
Early-stage preclinical discovery
Area
Drug discovery
Status
Ongoing
Patent Status
The chemical composition of their lead compound is patented
Background
HDAX Therapeutics is a small molecule preclinical stage drug discovery company developing a targeted therapeutics platform for safe and efficacious treatment of Histone Deacetylase (HDAC)-driven pathologies such as neuropathies and cancers with high unmet medical needs.
Aims, Hypothesis & Results
HDAX Therapeutics has developed a unique method of targeting HDAC6, a protein implicated in various diseases. Their research has shown promising results in increasing the lifespan of animal models. They have also successfully addressed common challenges in drug development, such as weak binding, off-target toxicities, and poor pharmacokinetic profiles. Their lead HDAC6 inhibitor has shown the ability to cross the blood-brain barrier, which sets it apart from similar drugs. This could allow for effective treatment of diseases affecting the central nervous system.
Timeline
HDAX Therapeutics will first focus on clinical candidate selection, a crucial step in drug development, involves refining promising molecules from earlier stages, evaluating their efficacy, ensuring their safety, and determining their pharmacokinetic properties. To assess the overall potential, the molecules' tolerability and efficacy will then be evaluated in indication-specific animal models.
Clinical Candidate Selection
Required Funding: $250,000
Duration: 12 Months
VitaDAO Board Evaluation Write-up
HDAX Therapeutics has a strong team of professionals, including experienced scientists and a renowned professor in the field. The proposal highlights potential risks, such as the early validation stage and the industry's competitive landscape. However, the team has a history of collaboration and successful academic projects, resulting in several publications and patents. The company has secured non-dilutive funding and won various pitch competitions, showcasing its potential.
Latest Project Updates
The company announced the first closing of an oversubscribed US$3.2 (CA$4.3) million seed round. The financing was led by SeedFolio, FACIT, and Toronto Innovation Acceleration Partners (“TIAP”), with participation from Eos Bioinnovation (“Eos”), Ontario Centre of Innovation (“OCI”), and other investors. Proceeds from this financing will support the company’s progress towards preclinical development candidate nomination and further advancement of its pipeline programs.
Discover more projects & initiatives

The Longevity Prize
The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.

The VitaDAO Longevity Fellowship
The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.

Humanity - Proprietary Aging Score App
Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

BE Therapeutics - Brain Tissue Replacement
The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.